Women & HIV
Women & HIV
WHO Affirms That Women at Risk for HIV Should Continue To Use Injectable Contraceptives
- Details
- Category: HIV Sexual Transmission
- Published on Friday, 02 March 2012 00:00
- Written by Liz Highleyman
The World Health Organization (WHO) has affirmed its 2009 policy that women living with or at risk for HIV should continue to use hormonal contraception, despite conflicting results from recent studies suggesting that oral or injectable hormones may increase the risk of HIV infection.
Pets and Parenthood Help Women Cope with HIV
- Details
- Category: Women & HIV
- Published on Friday, 27 January 2012 00:00
- Written by Liz Highleyman
Identification with their role as a mother, grandmother, or pet owner helped women with HIV cope with having a chronic disease, according to a study published in the January 2012 online edition of Women's Health Issues.
Quad Pill Works as Well as Atazanavir Combo at 48 Weeks
- Details
- Category: HIV Treatment
- Published on Friday, 23 September 2011 00:00
- Written by Press Release
The experimental Quad pill -- a once-daily single-tablet regimen containing the integrase inhibitor elvitegravir, the novel boosting agent cobicistat, and the NRTIs tenofovir and emtricitabine -- met a 48-week primary endpoint demonstrating non-inferiority to a boosted atazanavir regimen, Gilead Sciences announced this week. Both combinations suppressed HIV RNA in about 90% of treatment-naive HIV patients, but fewer people discontinued the Quad due to side effects. 
EACS: Do Women with HIV Experience Earlier Menopause?
- Details
- Category: Women & HIV
- Published on Thursday, 13 October 2011 00:00
- Written by Liz Highleyman
Premature menopause may be more common among women with HIV, but the difference is primarily driven by women with advanced immune deficiency, according to study results presented at the 13th European AIDS Conference (EACS 2011) this week in Belgrade.
ICAAC: Cobicistat Matches Ritonavir as Booster, Studies Clarify Effects on Kidney Function
- Details
- Category: HIV Treatment
- Published on Friday, 23 September 2011 00:00
- Written by Liz Highleyman
The experimental pharmacoenhancing agent cobicistat continues to work as well as ritonavir for boosting other antiretroviral drugs, according to findings published in the September 24, 2011, issue of AIDS.
In addition, 2 studies presented this week at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) shed further light on cobicistat's impact on the kidneys, indicating that it reduces estimated but not actual glomerular filtration rate (GFR) by altering activity in the proximal renal tubules.
Web Design and Development by